SCHEMBL24317323

SCHEMBL24317323

CCCC1(OC)CN(Cc2ccccc2S(=O)(=O)N2CCOCC2)C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.43
PTGDR2 Q9Y5Y4 1/20 0.43
USP2 O75604 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
ALDH1A1 P00352 4/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TSHR P16473 2/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HTT P42858 1/20 0.38
CYP2D6 P10635 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
CYP2A13 Q16696 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26636508 0.94 PTGDR2 (0.44) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL26620499 0.91 NPC1 (0.45) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL27010436 0.86 PTGDR2 (0.44) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL26620187 0.84 NPC1 (0.46) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL24316060 0.82 PTGDR2 (0.48) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL27010308 0.82 NPC1 (0.44) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL26636472 0.82 PTGDR2 (0.46) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL26620491 0.81 PTGDR2 (0.46) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL26620496 0.81 PTGDR2 (0.46) NPC1PTGDR2USP2CYP3A4CYP2C9
SCHEMBL24316265 0.81 PTGDR2 (0.45) NPC1PTGDR2ALDH1A1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed